Injectable medications for lowering cholesterol
Pro Research Analysisby 
Searched over 200M research papers
Overview of Injectable Medications for Lowering Cholesterol
Injectable medications have become important options for lowering cholesterol, especially for patients who cannot reach their cholesterol goals with oral drugs like statins or who are statin-intolerant. These medications target different pathways to reduce low-density lipoprotein cholesterol (LDL-C), which is a major risk factor for cardiovascular disease 1269.
PCSK9 Inhibitors: Evolocumab, Alirocumab, and Ongeriecimab
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are monoclonal antibodies that help the liver remove more LDL-C from the blood. Evolocumab and alirocumab are the most widely used PCSK9 inhibitors. They are given as subcutaneous injections, usually every two to four weeks 12810.
- Efficacy: These drugs can lower LDL-C by about 50-60% when added to statin therapy 810. Ongeriecimab, a newer PCSK9 inhibitor, has shown similar strong LDL-C reductions (over 70%) in recent studies .
- Safety: PCSK9 inhibitors are generally well tolerated. The most common side effects are mild and include injection-site reactions, nasopharyngitis, joint pain, and back pain 1258. Serious side effects are rare.
Small Interfering RNA (siRNA) Therapy: Inclisiran
Inclisiran is a first-in-class siRNA therapy that works by blocking the production of PCSK9 in the liver. It is given as a subcutaneous injection twice a year after two initial doses 3469.
- Efficacy: Inclisiran can lower LDL-C by about 40-50% in patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia who need more LDL-C reduction despite statin therapy 3469.
- Safety: The most common side effect is injection-site reaction. Other side effects, such as joint stiffness and mild infections, are similar to placebo 346. Long-term safety and effects on cardiovascular outcomes are still being studied .
Antisense Oligonucleotides and Other Injectable Agents
Other injectable agents include antisense oligonucleotides like mipomersen and drugs targeting angiopoietin-like protein 3 (such as evinacumab). These are mainly used for rare, severe inherited cholesterol disorders .
- Efficacy: These drugs can significantly lower LDL-C and other lipid parameters, but are less commonly used than PCSK9 inhibitors or inclisiran .
- Safety: Mipomersen is associated with liver-related side effects, such as increased liver enzymes and fat accumulation in the liver, as well as injection-site reactions and flu-like symptoms 12. Safety data for some newer agents are still limited.
Physician Preferences and Patient Considerations
Physicians value the strong LDL-C lowering effect of injectable therapies, especially for patients who have trouble sticking to daily oral medications. Less frequent dosing, such as with inclisiran (every six months), is preferred for patients with poor adherence . Cardiologists are more likely to choose injectable therapies than primary care physicians, especially for high-risk patients .
Conclusion
Injectable medications for lowering cholesterol, including PCSK9 inhibitors (evolocumab, alirocumab, ongericimab), siRNA therapy (inclisiran), and antisense oligonucleotides, offer effective and generally well-tolerated options for patients who need additional LDL-C reduction beyond what oral drugs can provide. These therapies are especially valuable for high-risk patients and those who cannot tolerate statins. Ongoing research will further clarify their long-term safety and impact on cardiovascular outcomes 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic